Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drugEmilia Alors‐Pérez, Justo P. Castaño, Ricardo Blázquez‐Encinas et al.|Journal of Experimental & Clinical Cancer Research|2021Cited by 60
The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancerDaniel Hormaechea‐Agulla, Raúl M. Luque, Enrique Gómez‐Gómez et al.|The FASEB Journal|2017Cited by 52
The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressivenessDaniel Hormaechea‐Agulla, Raúl M. Luque, Manuel D. Gahete et al.|Molecular Cancer|2017Cited by 51
Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumorsSergio Pedraza‐Arévalo, Justo P. Castaño, Emilia Alors‐Pérez et al.|Translational research|2022Cited by 22
Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate CancerEnrique Gómez‐Gómez, Raúl M. Luque, Juan M. Jiménez‐Vacas et al.|Journal of Clinical Medicine|2019Cited by 17